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836Objective: Aortic valve repair has encouraging midterm results in selected patients. However, neither the long-
term results of cusp extension nor the durability of different pericardial fixation techniques has been reported. Our
goal was to address these issues.
Methods: Seventy-eight children with severe rheumatic aortic regurgitation (mean age 12  3.5 years) under-
went aortic valve repair using cusp extension over a 15-year period, with fresh autologous pericardium in
53 (67.9%), glutaraldehyde-fixed bovine pericardium in 9 (11.5%), and PhotoFix bovine pericardium (Sorin
CarboMedics, Milano, Italy) in 16 (20.5%). Fifty-seven children (73.1%) underwent concomitant mitral valve
repair, and 8 children (10.3%) underwent tricuspid valve repair.
Results: There was 1 operative death from left ventricular failure. During a median follow-up of 10.7 years (range
1 month to 16.4 years), 1 late death occurred and 15 patients (19.7%) required reoperation at a mean of 43 33.7
months (range 1 month to 9 years), 9 within the autologous pericardium group (18%), 3 within the bovine peri-
cardium group (33%), and 3 within the PhotoFix pericardium group (19%). Freedom from reoperation was
96%  2.3% at 1 year, 87.5%  3.9% at 5 years, 80.7%  4.9% at 10 years, and 75.3%  6% at 15 years,
and was significantly decreased in the bovine pericardium group (P ¼ .039). On multivariable analysis, greater
age (hazard ratio 1.25, P< .001) and acute rheumatic carditis (hazard ratio 8.15, P ¼ .001) at operation were
significant predictors of reoperation.
Conclusions: Aortic cusp extension provides adequate valve repair in a large proportion of children with rheu-
matic aortic regurgitation. Fresh autologous and PhotoFix pericardium trended toward better durability than
glutaraldehyde-fixed bovine pericardium. (J Thorac Cardiovasc Surg 2010;140:836-44)Earn CME credits at
http://cme.ctsnetjournals.org
Surgical management of aortic regurgitation in the young is
problematic because of the lack of an ideal valve substitute
within this age group. Prosthetic valves carry significant
drawbacks, such as difficult lifelong anticoagulation and
panus formation for mechanical valves, and rapid deteriora-
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The Journal of Thoracic and Cardiovascular Surgapproaches have been used, such as aortic homo- or autograft
(Ross procedure) valvular replacement2; however, they have
not demonstrated their superiority in rheumatic valvular dis-
ease.3 Rheumatic mitral valve (MV) repair has been shown
to be feasible and to have good midterm results.4 This has
stimulated the development of techniques for aortic valve
(AV) repair, which could theoretically result in optimal hemo-
dynamic conditions, avoiding anticoagulation and potentially
allowing normal aortic annulus growth. Efforts have been fo-
cused on patient selection and subgroups amenable to repair.
Duran et al5 developed the cusp extension technique for aortic
regurgitation caused by cusp retraction, the most common le-
sion in rheumatic aortic disease. We previously reported our
midterm results with a highly standardized and reproducible
modification to the technique,6 with actuarial survival of
97% at 1 and 3 years, exacerbation of aortic regurgitation
from grade I to II in only 2.5% of patients, no significant in-
crease in peak systolic transaortic gradient, and no reopera-
tions for relapsing aortic regurgitation during follow-up.
Several midterm reports on the same technique have reported
similar results in children, with mean follow-ups of 5.2 years7
and 4.6 years,8 but no long-term results to this date. Further-
more, differently fixed pericardium has been used, and the re-
sults of these different forms of pericardium have not beenery c October 2010
Abbreviations and Acronyms
AI ¼ aortic insufficiency
AV ¼ aortic valve
HR ¼ hazard ratio
LVEDD ¼ left ventricular end-diastolic diameter
LVESD ¼ left ventricular end-systolic diameter
MV ¼ mitral valve
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Dreported. The aim of this study was to update our cohort to re-
port the long-term results of the cusp extension technique for
repair of rheumatic aortic regurgitation in children, assess the
relative durability of different materials for cusp extension,
and identify risk factors for reoperations.
PATIENTS AND METHODS
The study was reviewed and approved by the local ethics committee, and
patient consent was waived.
Demographics
From March 1993 to July 2007, 78 consecutive children underwent cusp
extension AV repair for rheumatic aortic regurgitation caused by cusp re-
traction. Indications for operation included the presence of grade III or IV
aortic insufficiency (AI) resulting in progressive increase in left ventricular
dimensions. Eight patients had peak systolic AV gradients greater than 20
mm Hg. Patient demographics are summarized in Table 1. All of the patients
were from African and Asian countries and had a well-documented history
of rheumatic fever determined by the revised Jones’ criteria.9
Operative Procedure
Our tailored cusp extension technique was previously described in detail
and followed rigorously.6 All operations were performed by the senior
author (A.K.). In 57 patients, concomitant MV repair consisted of annulo-
plasty and various techniques as reported previously.4 After exposing the
AV, the cusps were inspected and measured with particular regard to
the length of the free edge, the height of the cusps and commissures, and
the appearance of the sinuses of Valsalva, aortic annulus, and sinotubular
junction. In all patients, tricuspid morphology of the AV was confirmed.
No patients had aortic cusp calcification. In 32 patients, a variable degree
of cusp thickening and retraction was found with no evidence of cusp pro-
lapse, 17 of whom required cusp shaving. Nine patients underwent concom-
itant aortic commissurotomy before proceeding to aortic cusp extension.
Among the 46 remaining patients, 31 had 1 aortic cusp prolapse with elon-
gation of the free edge and retraction in the height of the cuspal tissue: The
noncoronary cusp was prolapsed in 17 patients, the right coronary cusp was
prolapsed in 11 patients, and the left coronary cusp prolapsed in 3 patients.
Twelve patients had associated right and noncoronary cusp prolapse, 1 pa-
tient had right and left coronary cusp prolapse, and 1 patient had prolapse of
all 3 cusps. All 3 cusps were extended in all patients.
In 53 patients (67.9%), fresh autologous pericardium was used as the
cusp extension material. A large rectangular piece of anterior autologous
pericardium was cut and applied on a Dacron patch with its mesothelial sur-
face upward. Subsequently, the shape of each pericardial patch was traced
onto the Dacron patch, which served as a template for sizing, trimming,
and handling of the attached pericardium according to the established di-
mensions, as described previously.6 We used PhotoFix bovine pericardium
(CardioFix; Sorin CarboMedics, Milano, Italy) in 16 patients (20.5%), and
then glutaraldehyde-fixed bovine pericardium (St Jude Medical Inc, St Paul,
Minn) in 9 patients (11.5%) when Cardiofix was discontinued, in patientsThe Journal of Thoracic and Cawho had pericardial adhesions generated by repeated episodes of rheumatic
fever and pancarditis. The use of autologous pericardium already affected
by inflammatory reaction and fibrosis in these patients was not deemed suit-
able because of the risk of accelerated structural deterioration.8
The cusps were first thinned if their mobility was restricted, maintaining
a leathery consistency at cuspal free edges to better hold the sutures. A 5-0
polypropylene suture (Cardionyl; Pe´ters Pharm Lab, Bobigny, France) was
passed through the midpoint of the pericardial patch and the corresponding
cusp and tied with the knot on the aortic side. Each arm of the tied suture was
run up to the commissures and tied with the suture from the neighboring
cusp over a pericardial pledget outside the aorta. The Dacron patch was
then removed. The same procedure was repeated for each cusp with each
specifically corresponding scalloped pericardial patch.
When required, tricuspid annuloplasty was performed on a beating heart
after other valvar procedures were finished. Intraoperative transesophageal
echocardiography examinations were performed in all patients before skin
incision and after termination of cardiopulmonary bypass.
Follow-up
Transthoracic echocardiography was carried out in all patients before
surgery, before discharge from the hospital, and at 3 and 6 weeks postoper-
atively in the outpatient clinic of the Geneva University Hospitals before
returning to their countries of origin.
Doppler echocardiographic grade of AI was measured with color Dopp-
ler flow and graded from the width and length of the regurgitant jet in the left
ventricle (grade 0–IV) according to previously described criteria.10 Peak
gradient across the AV was estimated by measuring peak systolic velocity
from Doppler studies in the transthoracic 5-chamber or suprasternal notch
sagittal view. Left ventricular end-diastolic diameter (LVEDD), left ventric-
ular end-systolic diameter (LVESD), and left ventricular shortening fraction
were measured at midpapillary level in the standardized parasternal trans-
thoracic long- or short-axis position. Z-scores were calculated using the lat-
est formulas.11 Seventy-six of the 78 patients (97%) were thereafter
followed in outpatient clinics by cardiologists in their country of origin,
who periodically informed us of the patients’ evolution by filling out a ques-
tionnaire, including clinical, echocardiographic, and medication informa-
tion. Follow-up in this study was achieved until July 2009. We followed
published guidelines in reporting freedom from valve-related events.12
Statistical Analysis
Statistical analyses were performed with the Statistical Package for the So-
cial Sciences (SPSS Inc, Chicago, Ill). Data are presented as mean standard
deviation. Continuous variables were analyzed with the Student t test or the
related samples Wilcoxon signed-rank test when appropriate, and categoric
variables were analyzed with the chi-square test. Differences between cusp
extension material group continuous variables were analyzed with analysis
of variance with Bonferroni post hoc correction. Actuarial estimates were cal-
culated using the Kaplan–Meier method, and differences between curves
were assessed by the log-rank test. Univariate and stepwise Cox multivariable
regression analyses were used to identify the independent predictors of late
outcomes. Preoperative and operative variables with a univariate P less
than .1 or those judged to be clinically important were entered into the Cox
models. Hazards ratios for reoperation of risk factors were calculated using
univariate and multivariable Cox proportional hazards estimates. All statisti-
cal tests were 2-tailed. Methodological support was provided by the Clinical
Research Center, University of Geneva, and Geneva University Hospitals.
RESULTS
Early Outcome
The mean aortic crossclamping time was 73.9  35.2
minutes (range, 33–144 minutes) for 21 children undergoing
isolated AV repair and 112.1  34.7 minutes (range 58–195
minutes) for 57 children undergoing concomitant MV andrdiovascular Surgery c Volume 140, Number 4 837
TABLE 1. Patient characteristics
Variable
Entire study
population
N ¼ 78
Fresh autologous
pericardium
n ¼ 53
Glutaraldehyde-fixed
bovine pericardium
n ¼ 9
PhotoFix (Sorin CarboMedics,
Milano, Italy) bovine pericardium
n ¼ 16 P
Age (y) 12.3  3.5 11.9  2.7 14.5  8.9 12.4  2.8 .24y
Male 49 (63%) 33 (62%) 5 (56%) 11 (69%) .80z
Weight 33.4  9.6 kg 33.1  10.0 kg 47.0  12.5 kg 32.4  7.6 kg .36y
Acute rheumatic carditis* 4 (5%) 2 (3.8%) 1 (11.1%) 1 (6.3%) .65z
NYHA functional class
I or II 5 (6.4%) 3 (5.7%) 1 (11.1%) 1 (6.3%) .83z
III or IV 73 (93.6%) 50 (94.3%) 8 (88.9%) 15 (93.8%) .83z
Concomitant surgery
Mitral valve repair 57 (73%) 40 (75.5%) 5 (55.6%) 12 (75%) .45z
Tricuspid valve repair 8 (10%) 5 (9.4%) 0 (0%) 3 (18.8%) .31z
NYHA, New York Heart Association. *Active rheumatic carditis was based on clinical examination, serologic criteria, and surgical macroscopic evaluation. yOne-way analysis of
variance. zChi-square test.
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DAV repair. There was 1 operative death from left ventricular
failure. Two patients presented intraoperative suspected dy-
namic coronary ostia occlusion by the extension patches af-
ter crossclamp removal (evidenced by intractable ventricular
fibrillation), requiring cardioplegic arrest, valve repair ex-
ploration, and shortening of each cusp extension patch by
1 mm. Both patients subsequently regained normal sinus
rhythm and had an uneventful postoperative course.
Late Outcome
Follow-up was complete in 98.7% of the patients (76/77).
The patient lost to follow-up was from the early part of the
series. Mean and median follow-ups were 115.5  61.4
months and 128 months, respectively, ranging from 1 to
16.4 years overall. The median follow-up for the fresh autol-FIGURE 1. PhotoFix pericardium cusp extension 5 years later. Surgical
view of the repaired AV in a patient requiring reoperation for MV repair
5 years after PhotoFix (Sorin CarboMedics, Milano, Italy) cusp extension.
The extensions were pliable and presented no calcifications or retraction.
838 The Journal of Thoracic and Cardiovascular Surgogous pericardium group was 163 months (mean, 142 
54.9 months), 22 months for the bovine pericardium group
(mean, 43  38 months), and 75.5 months for the PhotoFix
pericardium group (mean, 71.7 21.3 months). One patient
died of sudden cardiac arrhythmia at home in the 55th post-
operative month, with apparently competent AV and MV. In
all patients, anticoagulation with warfarin began on the sec-
ond postoperative day and was stopped during the third post-
operative month until 1999; since then, patients did not
receive any anticoagulation unless another indication re-
quired it. No thromboembolic or hemorrhagic events were
observed up to the most recent follow-up examinations. Fif-
teen patients (19.7%) underwent reoperation for severe AV
dysfunction after a mean period of 42.9  33.7 months
(range, 1.2–108 months) from the initial AV repair, 9 within
the autologous pericardium group (18%), 3 within the glu-
taraldehyde pericardium group (33%), and 3 within the Pho-
toFix pericardium group (19%).
The mode of failure differed depending on the extension
material: Glutaraldehyde-fixed bovine pericardium pre-
sented deterioration from calcification; fresh autologous
pericardium underwent inflammatory cell infiltration and
a variable degree of retraction; PhotoFix pericardium was
surprisingly unaffected (Figure 1), and repair failure was
linked to continued rheumatic degeneration of the native
leaflets or annular dilatation.
Among the 15 patients requiring reoperation for AV re-
placement, 3 required concomitant MV replacement. Two
more patients required non–AV-related reoperation during
follow-up, 1 for MV replacement and 1 for MV repair.
Valve Function
Of the 76 patients followed up, 44 (58%) had no or trivial
AV regurgitation and 14 (18%) showed mild aortic regurgi-
tation at their last follow-up echocardiography. Eighteen
patients (24%) had significant aortic regurgitation during
follow-up. The aortic regurgitation was moderate to severe
(grade III) in 7 patients (9%) and severe (grade IV) in 11ery c October 2010
FIGURE 2. Survival curves after AV repair for rheumatic AV regurgitation in 78 children. A, Actuarial freedom from reoperation-free survival. B, Actuarial
freedom from AV-related event-free survival (including early and late deaths, reoperation, moderate to severe aortic regurgitation, endocarditis, and throm-
boembolism).
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tion and 4 patients with grade III aortic regurgitation all un-
derwent reoperation. The remaining 3 patients with grade III
regurgitation are being monitored, and 1 patient is scheduled
for reoperation.
Actuarial freedom from reoperation for significant aortic re-
gurgitation was 96%  2.3% at 1 year, 87.5%  3.9% at 5The Journal of Thoracic and Cayears, 84.6% 4.3% at 7 years, 80.7% 4.9% at 10 years,
78.7% 5.2% at 12 years, and 75.3% 6% at 15 years. For
the fresh autologous pericardium group, freedom from reoper-
ation was 98%  2% at 1 year, 91.9%  3.9% at 5 years,
83.5%  5.4% at 10 years, and 79.8%  6.2% at 15 years.
For the glutaraldehyde-fixed bovine pericardium group, free-
dom from reoperation was 88.9%  10.5% at 1 year,rdiovascular Surgery c Volume 140, Number 4 839
TABLE 2. Cox regression analysis of predictors for reoperation
Univariable Multivariable
Variable HR P 95% CI HR P 95% CI
Age 1.24 <.001 1.101.39 1.25 <.001 1.101.40
Male gender 0.57 .28 0.201.59 1.25 .70 0.413.86
Concomitant mitral operation 1.59 .48 0.455.62 1.21 .81 0.0954.29
Concomitant tricuspid operation 2.25 .21 0.637.99 2.45 .16 0.699.35
Acute rheumatic carditis 9.57 <.001 2.9231.35 8.15 .001 2.4527.11
Extension material .07 .78
Fresh autologous pericardium* 1 1
Glutaraldehyde-fixed bovine pericardium 5.31 .02 1.3021.66 2.01 .49 0.2814.52
PhotoFix bovine pericardium 1.81 .41 0.447.35 1.11 .90 0.235.38
Aortic commissurotomy 8.19 .007 1.7837.62 0.89 .94 0.0419.83
HR, Hazard ratio; CI, confidence interval. *Reference group.
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For the PhotoFix pericardium group, freedom from reopera-
tion was 93.8% 6.1% at 1 year, 81.3% 9.8% at 5 years,
and 81.3% 9.8% at 7 years. This difference was statistically
significant, with a higher reoperation rate in the bovine peri-
cardium group (log-rank test, P¼ .039; Figure 2, A). On uni-
variate analysis, greater age (hazard ratio [HR] 1.24,P<.001),
acute rheumatic carditis (HR 9.57, P<.001) at operation, ne-
cessity of aortic commissurotomy before cusp extension (HR
8.19, P ¼ .007), and use of glutaraldehyde pericardium (HR
5.31, P ¼ .02) were predictors of reoperation (Table 2). On
multivariable analysis, only greater age and acute rheumatic
carditis at operation were significant independent predictors
of reoperation.
AV-related event-free survival (including death, reopera-
tion, and moderate to severe aortic regurgitation) was
85%  4.2% at 5 years, 73.8%  5.4% at 10 years, and
68.8%  6.1% at 15 years after the initial operation
(Figure 2, B).TABLE 3. Transvalvular gradients
Variable
Fresh
autologous
pericardium
Glutaraldehyde-fixed
bovine pericardium
PhotoFix
pericardium
Preoperative 17.2  5.0 19.4  6.8 17.5  7.2
Discharge 16.0  5.5 15.7  4.8 14.4  6.9
P* .04 .007 .003
Latest follow-up 22.1  8.6 19.9  5.7 21.9  13.7
Py <.001 .03 .009
Increase per year 1.0  2.4 3.6  3.7 1.1  2.4
Pz * .02 1.0
*P value: comparison between the preoperative values versus those at discharge within
each treatment group using related samples Wilcoxon signed-rank test. yP value: com-
parison between the values at discharge versus those at latest follow-up within each
treatment group using related samples Wilcoxon signed-rank test. zP value: compar-
ison between the increase in peak transvalvular gradient per year, compared with the
reference group (*) using analysis of variance multiple comparisons with Bonferroni
post hoc comparison. Overall analysis of variance test of significance was P¼ .02. All
values are reported as mean  standard deviation, in millimeters of mercury unless
otherwise noted.
840 The Journal of Thoracic and Cardiovascular SurgTransvalvular Gradients
The peak gradients through the AV are shown in Table 3.
There was a significant increase in the peak gradient during
follow-up, from a mean postoperative value of 15.6  5.7
mm Hg to a mean of 21.8  9.5 mm Hg at the latest
follow-up (P < .001), regardless of the material used
for cusp extension. This represented an increase of
6.3  9.3 mm Hg, or 1.3  2.7 mm Hg/y, during follow-
up, which was markedly increased in the bovine pericardium
group (3.6  3.7 mm Hg/y, P ¼ .02).Left Ventricular Dimensions and Shortening
Fraction
Increased preload caused by aortic regurgitation resulted
in enlarged LVEDD and LVESD values preoperatively of
6.1  0.6 cm (z-score 4.1  1.1) and 4.0  0.5 cm (z-score
3.6  1.0), respectively. Mean LVEDD and LVESD were
significantly (P < .001) reduced at hospital discharge:
4.7  0.5 cm (z-score 1.5  1.3) and 3.6  0.6 cm (z-score
2.9  1.2), respectively. These values increased at latest
follow-up to 4.9  0.5 cm (z-score 2.3  2.2) and 3.4 
0.5 (z-score 2.7  1.8), respectively; these are significantly
increased when comparing discharge with follow-up
LVEDD and LVESD values (P < .001 for both) and
LVEDD z-scores (P ¼ .008), but not when comparing dis-
charge and follow-up values indexed to body surface area
(P ¼ .06 and .5, respectively) and z-scores (P ¼ .48). By
comparing the different cusp extension material groups,
there was no significant difference between their respective
preoperative (P¼ .37 and .29), discharge (P ¼ .72 and .51),
and follow-up (P ¼ .29 and .73, respectively) LVEDD and
LVESD values. Comparison of indexed values and z-scores
did not demonstrate any more significant differences
between groups.
The mean preoperative left ventricular shortening fraction
was 34.4%  3.3%, followed by a significant reduction
(P< .001) at the time of hospital discharge to 23.5% 
4.3%, and followed by a significant increase (P< .001) atery c October 2010
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cant differences between cusp extension material groups at
each time point (P ¼ .58, .17, and .24 respectively).
DISCUSSION
Long-term results in surgery for mitral regurgitation have
demonstrated that repair is advantageous over replacement in
terms of survival and incidence of thromboembolic and
bleeding complications.13 MV repair has thus become the
treatment of choice, and its feasibility has led to the recom-
mendation of earlier surgery, even in asymptomatic patients,
to preserve ventricular geometry and function.14 Part of these
advances has come from better understanding the causes and
specific mechanisms of mitral regurgitation and identifica-
tion of patient subgroups and the optimal repair technique
to be applied. A major limitation to the more generalized ap-
plication of AV repair is the absence of such a common
framework for valve assessment to guide the approach to
valve repair. Boodhwani and colleagues15 proposed a re-
pair-oriented functional nomenclature, similar to Car-
pentier’s pioneering classification of mitral regurgitation,16
dividing lesions into 3 types: I (mainly due to aortic dilata-
tion), II (cusp prolapse), and III (cusp retraction). Various se-
ries have reported encouraging midterm outcomes in
heterogeneous groups of patients undergoing AV repair.
Aicher and colleagues17 reviewed their experience in 640 pa-
tients (mean age, 56  17 years) undergoing AV repair for
insufficiency of all functional types and causes, with freedom
from reoperation at 5 and 10 years of 88% and 81% for bi-
cuspid valves and 97% and 93% in tricuspid valves, respec-
tively. Boodhwani and colleagues15 reported 264 patients
(median age, 55 years) with a 5-year survival of 95% 
3% and freedom from reoperation of 92% 4%. However,
freedom from reoperation was reduced in restricted (type III)
AVs (88% 9% vs 94% 4% in types I and II, P¼ .08),
and freedom from recurrent AI greater than 2 was signifi-
cantly lower for type III lesions than for type I or II lesions
(HR 2.6; 95% confidence interval, 1.1–11.6;P¼ .03). These
results are encouraging for a more widespread use of AV re-
pair. Nonetheless, specific subgroups of patients and their
optimal repair strategy need to be assessed. Furthermore,
these results must be confirmed in children. In practically
the only study in children, Bacha and colleagues18 reported
81 patients (median age, 8.6 years) with aortic regurgitation
from congenital causes, after balloon valvuloplasty or other
interventions, and a minority of rheumatic and endocarditic
causes, with estimated freedom from AV replacement of
72% 6% at 5 years and 54% 9% at 7.5 years, with a sig-
nificant decrease in left ventricular dimensions, showing that
surgical aortic valvuloplasty is a valid option with good inter-
mediate results for children and adolescents with aortic re-
gurgitation from a variety of causes.
We have focused our attention on patients with aortic
regurgitation caused by cusp retraction, the most commonThe Journal of Thoracic and Calesion in rheumatic aortic disease. We previously reported
our short and midterm results6 in 49 children (mean age,
11.5  2.7 years), with an actuarial survival of 97% at
3 years and no reoperations, and showed growth of the
repaired valves with no increase in peak systolic gradients
during follow-up. Grinda and colleagues8 reported 89
patients (mean age, 16  5 years) who underwent cusp
extension for rheumatic AV disease. Five-year survival
and freedom from aortic reoperation were 96% and 92%,
respectively. Bozbuga and colleagues7 reported 46 patients
with rheumatic valve disease (mean age, 35  12 years)
with survival of 98% at 8.6 years and freedom from reoper-
ation of 76.1% at 7.5 years. The longest available results
with this technique, with a follow-up of up to 16 years,
were reported by Al Halees and colleagues19 for 92 patients
(mean age, 30 years) with mostly rheumatic valve disease.
The survival was 85%. There were no episodes of thrombo-
embolism, and freedom from reoperation was 68% at 10
years and 47% at 16 years. We report significantly improved
results with our tailored, highly standardized modification to
triple cusp extension repair, with freedom from reoperation
of 81%  5% at 10 years and 75%  6% at 15 years.
Various materials have been used to extend the aortic
cusps, including fascia lata,20 heterologous (bovine) pericar-
dium,19 fresh autologous pericardium,6 and glutaraldehyde-
stabilized autologous pericardium.8,21 Duran and
colleagues5,22 compared the use of glutaraldehyde-fixed bo-
vine and autologous pericardium. At the short to mid-
term,5,22 bovine pericardium seemed to have significantly
worse outcomes, making them abandon this material for
cusp extension. At long-term follow-up, however, there
was no significant difference between the groups, with free-
dom from reoperation of 72% 6% at 10 years and 45%
8% at 16 years in the bovine pericardium group versus
68%  5% at 10 years and 47%  6% at 16 years in the
fresh autologous pericardium group.19 We confirm the initial
results of Duran and colleagues,5,22 with significantly worse
results with glutaraldehyde-fixed bovine pericardium at the
midterm, with freedom from reoperation of 78%  14%
at 7 years compared with 85%  4% for fresh autologous
pericardium and 81%  10% for PhotoFix bovine pericar-
dium. However, these results must be mitigated, because the
statistical significance of the log-rank analysis is limited by
the number of events and reaches significance based on a sin-
gle supplementary event in the glutaraldehyde pericardium
group; furthermore, this trend was not confirmed on multi-
variable analysis. The multivariable models used are also
limited by the number of events: There are 15 events for 8 de-
grees of freedom in the model (Table 2), although 5 to 10
times more events than degrees of freedom are usually rec-
ommended. Finally, the comparison of the rate of increase
of transvalvular gradients between the groups is confounded
by the relatively short follow-up in the glutaraldehyde peri-
cardium group relative to the other groups.rdiovascular Surgery c Volume 140, Number 4 841
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to be the better alternative in patients in whom autologous
tissue cannot be used. PhotoFix is an alternative to glutaral-
dehyde fixation, which uses dye-mediated photo-oxidation
rather than chemical cross-linking. Photo-oxidized bovine
pericardium is similar to untreated tissue in texture, pliabil-
ity, and shrinkage temperature, but unlike untreated tissue, it
possesses chemical, enzymatic, and in vivo stability. It is
thus non-immunogenic, biocompatible, and, unlike
glutaraldehyde-treated tissues, noncalcifying and noncyto-
toxic, thus allowing endothelization.23 Its use in valve recon-
struction has been limited24 because of poor results with
PhotoFix-based bioprostheses,25 although this was shown
to be due to valve design rather than fixation technique.
Study Limitations
This study has several limitations. It is a retrospective and
nonrandomized comparison of aortic cusp extension mate-
rials and represents a 15-year period of evolving experience
with AV repair. As such, any inferences drawn from these
data are limited by confounding variables, such as extent
of cusp disease, severity of preoperative AI, need for MV
or tricuspid repair, and duration of follow-up, which are dif-
ferently distributed between study groups. Our sample size
also limits our ability to perform extensive statistical adjust-
ments for these differences. Finally, follow-up echocardio-
graphic data were interpreted and analyzed, for the most
part, by the referring cardiologist in the patients’ country
of origin. This introduces the risk of estimator bias, because
the echocardiographic images could not be interpreted by an
independent echocardiography laboratory blinded to the sur-
gery, extension material, and clinical outcome.
CONCLUSIONS
Aortic cusp extension provides adequate valve repair in
a large proportion of children with rheumatic aortic regurgi-
tation. Fresh autologous and PhotoFix bovine pericardium
showed better durability, requiring fewer reoperations than
glutaraldehyde pericardium at midterm.
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Dr Emile Bacha (New York, NY). Although retrospective, this is
an important article for the following reasons: It comes from a cen-
ter with a large experience with AV repair, thus having digested the
learning curve. It reports on a homogeneous group of patients, all of
whom had rheumatic fever. It focuses on patch material, something
that hasn’t been done really in the past series.
It seems to me that AV repair as a technique is maturing and
much less controversial. However, it’s remarkable to note thatery c October 2010
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Doutcomes remain kind of stuck at 20% to 30% reoperation rate and
roughly 70% freedom from reoperation at 7 to 10 years. Thus, there
is still a lot of room for improvement, and one improvement could
come from better patch material. I have a few questions. Please con-
firm your current choice of patch material at this point in time.
Dr Myers. Fresh autologous pericardium.
Dr Bacha.What will be your second choice if the pericardium is
involved with the rheumatic carditis?
Dr Myers If it were available, we would use PhotoFix pericar-
dium because in our experience it doesn’t calcify or retract, and it
stays pretty much as is during its life. So that would be our second
choice if it’s not possible to use autologous pericardium.
Dr Bacha. Because it’s not available, what would you use then?
Dr Myers. Unfortunately, glutaraldehyde-fixed bovine pericar-
dium is our current strategy.
Dr Bacha. I was intrigued by the ostial occlusions that you
noticed in those 2 patients. Can you expand a bit on that, where
the patch is too long?
Dr Myers. We used our standard described technique for sizing
the patches. In these 2 cases, after releasing the crossclamp, we had
persistent ventricular fibrillation that was resistant to any form of
treatment. In these cases we reclamped the aorta, arrested the heart
and explored the extensions, and removed 1 mm of height from
each extension. In each case, the patients were weaned off bypass
without any trouble.
Dr Bacha. Was there any echo guidance with this? Could you
see that the patch extensions were occluding the ostium?
Dr Myers. Indeed, that was a help in the diagnosis.
Dr Bacha. Some people have recently advocated placing those
extension patches at the base of the cusp as opposed to on the free
edge of the cusp. In rheumatic fever you have a traction of the free
edge, but is that something that could be useful in this particular dis-
ease?
Dr Myers. That could be useful. From a technical standpoint,
we found it easier to work with the existing cusps, shaving them,
if necessary, to make them pliable. But it’s true that in our experi-
ence, for example, in the PhotoFix pericardium group, the mode
of recurrent regurgitation was annular dilation in 1 patient and
renewed retraction on the native cusps in 2 patients. One could hy-
pothesize that these 2 patients would not have required a reoperation
had they had their own cusps removed entirely and the valve
reconstructed completely from the base of the cusps.
Dr Bacha. What about the patient who presents with severe
aortic regurgitation and is hemodynamically unstable with active
rheumatic fever or unresolved rheumatic fever? Would you recom-
mend the AV repair in that situation?
Dr Myers. It depends entirely on how the tissues appear when
we look at the AV. Let’s say, ideally, yes. But we can, in those
cases, find that the aortic cusps are very friable and that sutures
do not hold very well on that. So our strategy would be to attempt
a repair; however, it’s not always technically feasible.
Dr Bacha. I would be careful with that, because if your rheu-
matic fever is not burnt out you may have rheumatic fever on the
repaired valve.
Dr Myers. On the extended cusps, absolutely.
Dr Gerhard Ziemer (Tuebingen, Germany). Dr Myers, you
have to be congratulated for your work and results. And obviouslyThe Journal of Thoracic and Cain medicine when you do something and have good results, it’s the
right thing.
However, I have a conceptual problem with what you’re doing
and claiming. With the use of fresh autologous pericardium in
this position, as you use in MVs, we know that fresh pericardium
retracts. So what is the trick or the reason that you replace your
cusps with fresh autologous pericardium and it doesn’t shrink.
Do you use a special size?
I can say in those MVs where I used pericardium and occasion-
ally forgot or glutaraldehyde wasn’t there, after 3 months I had
some leak because the pericardium was retracting. So why doesn’t
this happen in your cases?
DrMyers. In our experience, the mode of failure differs depend-
ing on the material, and it’s a choice of which is the best available
option. Fresh autologous pericardium retracts with time. With glu-
taraldehyde-fixed pericardium, we found that these rapidly calcify,
independently of the length of fixation.
Dr Ziemer. But you did not use autologous glutaraldehyde-
fixed pericardium. You only had bovine, and this is completely
different. Did you ever try fresh autologous glutaraldehyde-fixed
pericardium?
DrMyers. We have an initial, very limited experience with that,
and we had very rapid calcification in the aortic position, which is
why we abandoned that.
Dr Ziemer. Okay. Thank you.
Dr Muhammad Ali Mumtaz (Norfolk, Va). I have a couple of
comments and 1 question. I’m very curious to see, if you don’t have
an answer, if the audience or moderators might.
A number of studies, including one from Cleveland Clinic,
which I was part of, in which glutaraldehyde-treated pericardium,
autologous pericardium, was used, typically there is no early calci-
fication. Late retraction and scarring do happen.
But recently I had the misfortune, or fortune, to use CorMatrix,
which is an acellular submucosa of the intestine, in 2 patients. In the
second patient, the posterior commissure bicuspid valve dehisced at
the attachment. So I had to go back, and thinking I would replace
the valve, once I noticed that the commissure had dehisced, I essen-
tially just reattached it. But to my pleasant surprise, just as the
company says, the leaflets were entirely replaced by normal tissue.
I could not distinguish what was normal and what was not. So I’m
curious to know if you have entertained using that? Or if certainly
there is no pericardium, why not use CorMatrix (Atlanta,
Ga), which is acellular or decellularized submucosa of the
intestine?
If you don’t have experience, I’m just curious to know if the
moderators or anybody in the audience has and what have they
found in terms of their durability. I’ve only used it in the last
year, and so I really don’t have follow-up information.
Dr Myers. I have no experience with the CorMatrix in intracar-
diac situations, only as an extracardiac material (to minimize peri-
cardial adhesions). But I don’t know if one of the moderators has
experience with intracardiac use.
Dr Tweddell. I have no experience with it, but I think you’ve all
sort of hit on the point: It’s really a materials problem, right? You’re
able to reconstruct a competent valve at the end of the procedure;
it’s just trying to find something that will hold up and be as durable
as cusp tissue normally is.rdiovascular Surgery c Volume 140, Number 4 843
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DDr Bacha. I don’t have any experience either, but I’m thinking
along the same lines as well.
Dr A. Charles Yankah (Berlin, Germany). Why didn’t you
use anticalcification-treated glutaraldehyde to mitigate calcifica-
tion?
Dr Myers. That’s a good proposition. Unfortunately, it’s not
freely available in our center. And given our initial experience
with fresh autologous pericardium, which was relatively good to
the midterm, we continued on that line; but that is indeed a line
of thought that could be pursued.
DrYankah.Did you make any study on the immune response in
the explanted glutaraldehyde, just to identify any tissue reaction,
because this could trigger the left ventricular structural valve
deterioration and calcification.
Dr Myers. No, we did not. All we did was standard cross-
sections to get an idea of what was happening in terms of fibrotic
reaction, retraction, calcification, and so forth. We have not done
any more detailed immunologic research in that line.
Dr Yankah. In view of inflammation of the tissue, did you an-
ticipate or try to treat these patients with anti-inflammatory drugs?
Dr Myers. No, that is not part of our management. Of course,
with rheumatic fever or rheumatic heart disease, that is an ongoing
process and an issue over time, and that could be another line of
further research.
Dr Yankah. Did you put these patients on long-term penicillin
to prevent recurrence of rheumatic fever?
Dr Myers. Absolutely.
Dr Andres Jorge Schlichter (Buenos Aires, Argentina). I want
to congratulate you on a nice presentation, and I’m not going to ask
you anything about the technique because I’m a fan of autologous
fresh pericardium.
Where did you get this number of patients with rheumatic fever
who are so young in Switzerland? We don’t have them in Argen-
tina. We don’t have them in underdeveloped countries anymore.
An 8-year-old with aortic incompetence due to rheumatic fever is
extremely rare. We don’t have that in Argentina, and that’s an un-
derdeveloped country. There used to be rheumatic fever in Argen-
tina, but not anymore. What we usually observe now is aortic844 The Journal of Thoracic and Cardiovascular Surgincompetence caused by invasive cardiology (balloon dilation of
bicuspid valves). We don’t see these tricuspid valves. Did you
import these patients?
DrMyers. Indeed, they were imported. We work with a human-
itarian association, and we are a reference center for these patients.
Dr Schlichter. Okay. Excellent answer.
Dr Christian Brizard (Melbourne, Australia). We have used
the cusp extension technique in both Paris and Melbourne with au-
tologous pericardium treated with glutaraldehyde. In Melbourne
we operate on aboriginal patients, and the incidence of aortic regur-
gitation in this population is relatively high, but much lower than
mitral regurgitation. We have a ratio of 1:10 AV surgery compared
with MV surgery.
My question is relevant to the same topic as the previous ques-
tion. In Paris we operated on patients through the Chain of Hope,
or ‘‘La Chaine de L’Espoir,’’ and we received patients from North
Africa mostly. It is notoriously difficult to have follow-up infor-
mation on these patients. We had extensive experience with this
technique, and it seemed that at midterm follow-up we had
good results. But when you do obtain long-term follow-up of
these rheumatic patients, it’s not as shiny. Therefore, the current
recommendation of the Chain of Hope, when we receive similar
patients in France now, is to use mechanical valve replacement
rather than cusp extension. The mechanical valve in the aortic po-
sition may tolerate antiplatelet therapy in these countries and has
good outcome.
Dr Myers. Of course, in a long-term study such as this, the
quality of the data is of utmost importance. The humanitarian asso-
ciation with which we are working, Terre Des Hommes, has a sys-
tem in place that guarantees follow-up with cardiologists, often
trained by the association, in northern Africa who can perform
the follow-up and get the follow-up data. We are updated yearly
with their data and involved in any decisions on reoperations.
The long-term follow-up and results in these patients are of utmost
importance, especially when offering an option that has a 20% to
30% reoperation rate.
Dr Bacha. Thank you, Dr Myers. We’re over time, so we’re
going to have to move on.ery c October 2010
